Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Since late 2019, the new SARS-CoV-2 virus belonging to the <i>Coronaviridae</i> family has been responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral therapies, mostly derived from previous epidemics, were initially repurposed to fight this not rarely...
Main Authors: | Massimo Franchini, Daniele Focosi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Life |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-1729/14/2/214 |
Similar Items
-
The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19
by: Daniele Focosi, et al.
Published: (2021-02-01) -
Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience
by: Maria Grazia Cusi, et al.
Published: (2021-07-01) -
The Three Pillars of COVID-19 Convalescent Plasma Therapy
by: Massimo Franchini, et al.
Published: (2021-04-01) -
Hyperimmune Globulins for the Management of Infectious Diseases
by: Ilaria Pati, et al.
Published: (2023-07-01) -
Convalescent Plasma for the Treatment of Severe COVID-19
by: Franchini M, et al.
Published: (2021-02-01)